Skip to content Rheos Medicines
Rheos Medicines Mobile Menu Toggle navigation
  • About
    • Company Overview
    • Our Leadership
    • Our Board of Directors
    • Our Founders & Advisors
  • Scientific Approach
    • Our Platform
    • Our Product Engine
  • Pipeline & Programs
  • Careers
    • Join Us
    • Our Team
  • News
  • Contact
  • Twitter
  • LinkedIn
Rheos Medicines
  • About
    • Company Overview
    • Our Leadership
    • Our Board of Directors
    • Our Founders & Advisors
  • Scientific Approach
    • Our Platform
    • Our Product Engine
  • Pipeline & Programs
  • Careers
    • Join Us
    • Our Team
  • News
  • Contact
Rheos Medicines
  • About
    • Company Overview
    • Our Leadership
    • Our Board of Directors
    • Our Founders & Advisors
  • Scientific Approach
    • Our Platform
    • Our Product Engine
  • Pipeline & Programs
  • Careers
    • Join Us
    • Our Team
  • News
  • Contact

Press Releases

  • December 17, 2020
    Rheos Medicines and PatientsLikeMe Announce Strategic Collaboration to Investigate Underlying Metabolic Drivers of Immune-Mediated Disease
  • October 21, 2020
    Rheos Medicines Appoints Dania Rabah, Ph.D., as Chief Scientific Officer
  • September 28, 2020
    Rheos Medicines to Participate in Stifel 2020 Immunology and Inflammation Virtual Summit
  • February 18, 2020
    Rheos Medicines to Present at the Cowen and Company 40th Annual Health Care Conference
  • December 19, 2019
    Rheos Medicines Announces Worldwide Collaboration with Roche to Discover and Develop Novel Medicines in the Field of Immunometabolism
  • December 12, 2019
    Rheos Medicines Announces Publication of Perspective in Cell Metabolism Highlighting the Rationale and Potential of Employing Principles of Immunometabolism to Discover and Develop Novel Medicines
  • October 21, 2019
    Rheos Medicines Appoints Barbara S. Fox as Chief Executive Officer
  • March 07, 2019
    Rheos Medicines to Present at the Cowen and Company 39th Annual Health Care Conference
  • October 10, 2018
    Rheos Medicines Expands Leadership Team with Appointments of Gad Soffer as Chief Operating Officer and J. Duncan Higgons to Board of Directors
  • March 22, 2018
    Third Rock Ventures Launches Rheos Medicines with $60 Million in Series A Funding to Harness Immunometabolism to Develop Precision Medicines for Immune-mediated Diseases
  • Twitter
  • LinkedIn
Rheos Medicines
  • Contact
  • Site Credits

© 2021 Rheos Medicines